Thomas J. Weber

Thomas J. Weber

Endocrinology

30 Duke Medicine Cir
Durham, NC 27710

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 37 publications

Clinical Pearls From JCEM Case Reports: ENDO 2025.

Clinical Pearls From JCEM Case Reports: ENDO 2025.

Journal: JCEM case reports

Published: August 25, 2025

Secondary fracture prevention after vertebral, femur or pelvic fracture at US academic medical center.

Secondary fracture prevention after vertebral, femur or pelvic fracture at US academic medical center.

Journal: Archives of osteoporosis

Published: July 07, 2025

Pharmacodynamic Exposure-Response Analysis of Fracture Count Data Following Treatment with Burosumab in Patients with XLH.

Pharmacodynamic Exposure-Response Analysis of Fracture Count Data Following Treatment with Burosumab in Patients with XLH.

Journal: Journal of clinical pharmacology

Published: June 25, 2024

Intra-articular Calcaneal Fractures: A Report of Cases and Comments on Preoperative Management.

Intra-articular Calcaneal Fractures: A Report of Cases and Comments on Preoperative Management.

Journal: Nigerian journal of clinical practice

Published: June 22, 2023

Long-term Burosumab Administration Is Safe and Effective in Adults With X-linked Hypophosphatemia.

Long-term Burosumab Administration Is Safe and Effective in Adults With X-linked Hypophosphatemia.

Journal: The Journal of clinical endocrinology and metabolism

Published: April 05, 2022

Efficacy of Burosumab in Adults with X-linked Hypophosphatemia (XLH): A Post Hoc Subgroup Analysis of a Randomized Double-Blind Placebo-Controlled Phase 3 Study.

Efficacy of Burosumab in Adults with X-linked Hypophosphatemia (XLH): A Post Hoc Subgroup Analysis of a Randomized Double-Blind Placebo-Controlled Phase 3 Study.

Journal: Calcified tissue international

Published: January 20, 2022

Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension.

Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension.

Journal: RMD open

Published: April 27, 2021

Reply to: Burosumab for Tumor-Induced Osteomalacia: not Enough of a Good Thing.

Reply to: Burosumab for Tumor-Induced Osteomalacia: not Enough of a Good Thing.

Journal: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research

Published: March 21, 2021

Diagnosis and Management of Tumor-induced Osteomalacia: Perspectives From Clinical Experience.

Diagnosis and Management of Tumor-induced Osteomalacia: Perspectives From Clinical Experience.

Journal: Journal of the Endocrine Society

Published: March 15, 2021

Burosumab for the Treatment of Tumor-Induced Osteomalacia.

Burosumab for the Treatment of Tumor-Induced Osteomalacia.

Journal: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research

Published: June 30, 2020

Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials.

Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials.

Journal: JAMA

Published: February 05, 2020

Molecular Control of Phosphorus Homeostasis and Precision Treatment of Hypophosphatemic Disorders.

Molecular Control of Phosphorus Homeostasis and Precision Treatment of Hypophosphatemic Disorders.

Journal: Current molecular biology reports

Published: December 25, 2019

Showing 1-12 of 37

Last Updated: 09/26/2026